TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37060288

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 8238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8238
Study: 37060420

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy - three sessions each week for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy
Number of subjects: 32
Study: 37060431

Group type: EXPERIMENTAL
Intervention: PRL3-zumab
Number of subjects: 27
Study: 37060432

Group type: EXPERIMENTAL
Intervention: Relugolix in combination with abiraterone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Relugolix in combination with apalutamide
Number of subjects: 25
Study: 37060448

Group type: EXPERIMENTAL
Intervention: Subventricular zone distance (SVD) measurement from tumor edge (definition 1)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Subventricular zone distance (SVD) measurement from tumor centroid (definition 2)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: SVD-updated survival model
Number of subjects: 187
Study: 37060458

Group type: EXPERIMENTAL
Intervention: Dersimelagon (oral selective MC1R agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37060545

Group type: EXPERIMENTAL
Intervention: High-dose VE303 (8.0 × 10^9 CFUs)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Low-dose VE303 (1.6 × 10^9 CFUs)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 79
Study: 37060708

Group type: EXPERIMENTAL
Intervention: Irradiated survivors of PFT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-irradiated survivors of PFT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 37060917

Group type: EXPERIMENTAL
Intervention: ChAdOx1 RVF vaccine (5 × 10^10 viral particles)
Number of subjects: 15
Study: 37060934

Group type: EXPERIMENTAL
Intervention: Early sexual debut (<15 years)
Number of subjects: 6079

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 6079

Group type: EXPERIMENTAL
Intervention: Interpretation of sexual intercourse
Number of subjects: 6079
Study: 37061109

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg once daily for 12 months
Number of subjects: 1778

Group type: COMPARATOR
Intervention: Placebo once daily for 12 months
Number of subjects: 1778
Study: 37061137

Group type: EXPERIMENTAL
Intervention: OverStitch Sx
Number of subjects: 33
Study: 37061169

Group type: EXPERIMENTAL
Intervention: Combination of CADe (GI-Genius; Medtronic) and Endocuff Vision (ECV; Olympus)
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Control group (CADe-assisted colonoscopy alone)
Number of subjects: 1316
Study: 37061234

Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: ETN monotherapy
Number of subjects: 371

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 371
Study: 37060915

Group type: EXPERIMENTAL
Intervention: Higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once daily for 5 days)
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Usual care (including low-dose corticosteroids 6 mg once daily for 10 days)
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Higher dose corticosteroids
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1272
Study: 37061361

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training during neoadjuvant chemoradiation therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unsupervised moderate-to-vigorous exercise after therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study: 37061619

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg IV, Q3weeks × 4) and nab-paclitaxel (100 mg/m2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 37
Study: 37061656

Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: DMF/DMF
Number of subjects: 125

Group type: COMPARATOR
Intervention: PBO/DMF
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: DMF/DMF and PBO/DMF
Number of subjects: 125
Study: 37061690

Group type: EXPERIMENTAL
Intervention: CDM test results
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (no CDM test)
Number of subjects: 236
Study: 37061693

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) with donor fresh frozen plasma (1.2 × individual plasma volume) performed within 6 hours after randomization.
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard of care (SOC) control arm.
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 274
Study: 37061715

Group type: EXPERIMENTAL
Intervention: Comprehensive supervised exercise program (CSEP) consisting of a 12-week intensive phase with 3 exercise sessions of 1 hour per week, followed by a maintenance phase with home exercises and monthly tele-consultations with a physiotherapist.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual supportive care (control group).
Number of subjects: 0
Study: 37061794

Group type: EXPERIMENTAL
Intervention: Dietitian-assisted, home-delivered, DASH-patterned groceries
Number of subjects: 176

Group type: COMPARATOR
Intervention: $500 monthly stipend
Number of subjects: 176
Study: 37061797

Group type: EXPERIMENTAL
Intervention: Community-to-Clinic Linkage Implementation Program (CLIP) with Barbershop Facilitation (BF) strategy
Number of subjects: 420

Group type: COMPARATOR
Intervention: Community-to-Clinic Linkage Implementation Program (CLIP) without Barbershop Facilitation (BF) strategy
Number of subjects: 420
Study: 37061796

Group type: EXPERIMENTAL
Intervention: LINKED-BP Program (home BP monitoring, BP telemonitoring through the Sphygmo app, CHW telehealth visits for education and counseling on lifestyle modification over 12 months)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 600
Study: 37061802

Group type: EXPERIMENTAL
Intervention: Screening with an implantable loop recorder (ILR) and initiation of anticoagulation upon detection of AF episodes lasting ≥6 minutes
Number of subjects: 5819

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 5819

Group type: EXPERIMENTAL
Intervention: Screening with ILR for participants with NT-proBNP above median
Number of subjects: 5819

Group type: COMPARATOR
Intervention: Usual care (control) for participants with NT-proBNP above median
Number of subjects: 5819
Study: 37061810

Group type: EXPERIMENTAL
Intervention: Vitamin D3 10 or 30 µg daily
Number of subjects: 813
Study: 37061829

Group type: EXPERIMENTAL
Intervention: Postpartum weight loss (PPWL) intervention (PPWL-only and GWG+PPWL conditions)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Gestational weight gain only (GWG-only) intervention
Number of subjects: 430
Study: 37062047

Group type: EXPERIMENTAL
Intervention: Bioresorbable-polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 2361

Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stent (DP-EES)
Number of subjects: 2361

Group type: EXPERIMENTAL
Intervention: Higher atherothrombotic risk (H-ATR)
Number of subjects: 2361

Group type: COMPARATOR
Intervention: Lower atherothrombotic risk (L-ATR)
Number of subjects: 2361
Study: 37062298

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200 mg + 50 mg
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200 mg + 30 mg
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study: 37062304

Group type: EXPERIMENTAL
Intervention: 1+1 PCV10
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: 1+1 PCV13
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: 0+1 PCV10
Number of subjects: 2501

Group type: EXPERIMENTAL
Intervention: 0+1 PCV13
Number of subjects: 2501

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2501
Study: 37062349

Group type: EXPERIMENTAL
Intervention: PAP therapy with lifestyle counseling
Number of subjects: 184

Group type: COMPARATOR
Intervention: Lifestyle counseling alone
Number of subjects: 184
Study: 37062359

Group type: EXPERIMENTAL
Intervention: High-UFA diet (MUFAs and/or PUFAs)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs) diet
Number of subjects: 113
Study: 37062422

Group type: EXPERIMENTAL
Intervention: TG103 3 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TG103 7.5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TG103 15 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TG103 22.5 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 37062500

Group type: EXPERIMENTAL
Intervention: First-line anti-TNF therapy
Number of subjects: 185
Study: 37062579

Group type: EXPERIMENTAL
Intervention: Stigma by association
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver's gender, biological relatedness, household composition, and family cohesion
Number of subjects: 0
Study: 37062581

Group type: EXPERIMENTAL
Intervention: MFG delivered via parent peers (MFG-PP)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: MFG delivered via community healthcare workers (MFG-CHW)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 636
Study: 37062580

Group type: EXPERIMENTAL
Intervention: Multiple family group intervention (16-week manualized intervention)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Multiple family group intervention
Number of subjects: 317
Study: 37062582

Group type: EXPERIMENTAL
Intervention: YDA + MFG
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: YDA
Number of subjects: 1260

Group type: COMPARATOR
Intervention: BSOC
Number of subjects: 1260
Study: 37062584

Group type: EXPERIMENTAL
Intervention: Family economic empowerment intervention (Suubi-Maka)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Bolstered usual care (control)
Number of subjects: 346
Study: 37062658

Group type: EXPERIMENTAL
Intervention: Dual immuno-oncology agents (IO+IO)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Combination of immuno-oncology drug and a tyrosine kinase inhibitor (TKI)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 675
Study: 37062804

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 5
Study: 37062834

Group type: EXPERIMENTAL
Intervention: Probiotic intervention for six months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Metformin (open-label)
Number of subjects: 180
Study: 37062953

Group type: EXPERIMENTAL
Intervention: Triplet combination of cabozantinib, nivolumab, and ipilimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab plus lenvatinib plus belzutifan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doublet combination therapy with immune checkpoint inhibitors or immune checkpoint and tyrosine kinase inhibitor
Number of subjects: 0
Study: 37063238

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine (Janssen/Johnson & Johnson), single dose
Number of subjects: 477234
Study: 37063316

Group type: EXPERIMENTAL
Intervention: SmartFeeding4Kids program (online self-guided intervention for parents)
Number of subjects: 89
Study: 37063373

Group type: EXPERIMENTAL
Intervention: Program Sustainability Action Planning Model and Training Curricula
Number of subjects: 11
Study: 37063543

Group type: EXPERIMENTAL
Intervention: i-CBT program (self-guided application)
Number of subjects: 41
Study: 37063762

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage (LAA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Left Atrium (LA)
Number of subjects: 47
Study: 37063904

Group type: EXPERIMENTAL
Intervention: Pancreas transplant alone (PTA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Simultaneous pancreas-kidney (SPK)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PTA with early graft thrombosis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PTA without early graft thrombosis
Number of subjects: 32
Study: 37063916

Group type: EXPERIMENTAL
Intervention: Humoral and cellular immune responses in vaccinated individuals with breakthrough infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effective cell-mediated immunity to SARS-CoV-2
Number of subjects: 0
Study: 37063970

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticagrelor-based 12-month DAPT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 0
Study: 37064032

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37064105

Group type: EXPERIMENTAL
Intervention: Right thoracoabdominal surgical approach (RTA)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Abdominal-transhiatal surgical approach (TH)
Number of subjects: 212
Study: 37064508

Group type: EXPERIMENTAL
Intervention: Intensive dietary counselling (target sodium intake <2.3 g/day)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 373
Study: 37065441

Group type: EXPERIMENTAL
Intervention: Conversational strategies used by trained conversation moderators
Number of subjects: 0
Study: 37065894

Group type: EXPERIMENTAL
Intervention: Training for Awareness, Resilience and Action (TARA)
Number of subjects: 35
Study: 37065899

Group type: EXPERIMENTAL
Intervention: CBD (Epidiolex®) 600 mg
Number of subjects: 10
Study: 37066150

Group type: EXPERIMENTAL
Intervention: PRISM-AC intervention (manualized, skills-based training program with four 30-60 minute sessions, facilitated family meeting, smartphone app, and advance care planning module)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: PRISM-AC intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (usual, non-directive, supportive care without PRISM-AC)
Number of subjects: 144
Study: 37066198

Group type: EXPERIMENTAL
Intervention: Behavioral treatments for RA
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Interventions targeting negative emotions
Number of subjects: 106
Study: 37066217

Group type: EXPERIMENTAL
Intervention: HD-tDCS (direct current)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: HD-tACS (alternating current)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Primary outcomes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 6
Study: 37066249

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily for four doses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 10
Study: 37066256

Group type: EXPERIMENTAL
Intervention: Tailored information multimedia app with text at one of three grade levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37066486

Group type: EXPERIMENTAL
Intervention: Brain voxel-based morphometry and lesional MRI analyses
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study: 37066690

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 37066788

Group type: EXPERIMENTAL
Intervention: Nuclear imaging screening for cardiac amyloidosis
Number of subjects: 0
Study: 37066828

Group type: EXPERIMENTAL
Intervention: VYC-15L treatment group
Number of subjects: 135

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 135
Study: 37066863

Group type: EXPERIMENTAL
Intervention: Turkish version of Fonseca Anamnestic Index (FAI/T)
Number of subjects: 249
Study: 37067031

Group type: EXPERIMENTAL
Intervention: Imaging-derived measures from the UK Biobank dataset
Number of subjects: 2314
Study: 37067193

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 (S3) outflow at Evolut node 4
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 (S3) outflow at Evolut node 6
Number of subjects: 204

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 204
Study: 37067353

Group type: EXPERIMENTAL
Intervention: t:slim X2 Insulin Pump with Control-IQ Technology
Number of subjects: 0
Study: 37067525

Group type: EXPERIMENTAL
Intervention: PARP inhibitors (PARPis)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Subsequent chemotherapy after PARPis
Number of subjects: 54
Study: 37067554

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 11
Study: 37067675

Group type: EXPERIMENTAL
Intervention: mRNA electroporated HBV-specific TCR T cells
Number of subjects: 6
Study: 37067785

Group type: EXPERIMENTAL
Intervention: Bioimpedance-guided fluid management
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study: 37067881

Group type: EXPERIMENTAL
Intervention: PMRT via Zoom and GI exposure
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PMRT via Zoom and personalized VR exposure
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PMRT based on audio-track guidance and personalized VR exposure
Number of subjects: 108
Study: 37067896

Group type: EXPERIMENTAL
Intervention: Tele-Savvy program
Number of subjects: 153
Study: 37067952

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab monotherapy
Number of subjects: 88
Study: 37068115

Group type: EXPERIMENTAL
Intervention: Severe dengue (SD)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Time from first symptom to hospital consultation over 2 days
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Being of Western European origin
Number of subjects: 163
Study: 37068272

Group type: EXPERIMENTAL
Intervention: Amubarvimab plus romlusevimab
Number of subjects: 807

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 807
Study: 37068273

Group type: EXPERIMENTAL
Intervention: Oral fluvoxamine (100 mg twice daily for 10 days) plus inhaled budesonide (800 mcg twice daily for 10 days)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 738
Study: 37068366

Group type: EXPERIMENTAL
Intervention: Escalating cannabis use pattern
Number of subjects: 149

Group type: COMPARATOR
Intervention: Low or no cannabis use pattern
Number of subjects: 149

Group type: COMPARATOR
Intervention: Medium stable cannabis use pattern
Number of subjects: 149

Group type: COMPARATOR
Intervention: High stable cannabis use pattern
Number of subjects: 149

Group type: COMPARATOR
Intervention: De-escalating cannabis use pattern
Number of subjects: 149
Study: 37068504

Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus mFOLFOX6
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX6
Number of subjects: 565
Study: 37068528

Group type: EXPERIMENTAL
Intervention: AF devices (AFX/AFX2 endograft system)
Number of subjects: 455

Group type: COMPARATOR
Intervention: PF devices (Cook Medical Zenith Flex; Gore Excluder; Medtronic Endurant II)
Number of subjects: 455
Study: 37068889

Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anaesthesia (TIVA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Inhaled volatile anaesthesia (INVA)
Number of subjects: 300
Study: 37068892

Group type: EXPERIMENTAL
Intervention: Induction of labour with oxytocin
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Repeated cervical ripening with prostaglandins (slow-release vaginal dinoprostone; oral misoprostol 25 µg; dinoprostone vaginal gel 2 mg)
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Repeated cervical ripening with prostaglandins
Number of subjects: 1494
Study: 37068906

Group type: EXPERIMENTAL
Intervention: Personalised AKI recommendations delivered by a physician and pharmacist team after AKI detection.
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Usual care arm (no real-time recommendations).
Number of subjects: 4000
Study: 37068952

Group type: EXPERIMENTAL
Intervention: Cranberry products
Number of subjects: 8857
Study: 37069007

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 243
Study: 37069359

Group type: EXPERIMENTAL
Intervention: Motixafortide and G-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37069364

Group type: EXPERIMENTAL
Intervention: SEL-037 0.2 mg/kg + SEL-110 0.1-0.15 mg/kg
Number of subjects: 152

Group type: COMPARATOR
Intervention: SEL-037 0.2 mg/kg alone
Number of subjects: 152

Group type: COMPARATOR
Intervention: SEL-110 withdrawn after week 12
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: SEL-037 0.2 mg/kg + SEL-110 0.15 mg/kg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: SEL-110 at doses up to 0.1 mg/kg
Number of subjects: 152
Study: 37069472

Group type: EXPERIMENTAL
Intervention: Double-lumen needle (DLN)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single-lumen needle (SLN)
Number of subjects: 200
Study: 37069490

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Smoking Cessation (BASC)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard Behavioral Treatment (ST)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 37069510

Group type: EXPERIMENTAL
Intervention: Institutional adaptation of symptom management care pathways
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Institutional adaptation process
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reasons for rejection of statements
Number of subjects: 10

Group type: COMPARATOR
Intervention: Institutional-level factors
Number of subjects: 10
Study: 37069518

Group type: EXPERIMENTAL
Intervention: Children living with HIV (CLHIV)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Children without HIV
Number of subjects: 157
Study: 37069527

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (60 min during the second hour of thrice weekly dialysis for 6 months)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No intradialytic exercise (control)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise
Number of subjects: 74